{
    "data": [
        {
            "id": "67a214df9d57a90001d4d600",
            "title": "How To Earn $500 A Month From Alphabet Stock Ahead Of Q4 Earnings (CORRECTED)",
            "description": " ",
            "image": "https://www.benzinga.com/files/images/story/2025/02/04/Alphabet-Google-Shutterstock.jpeg",
            "link": "https://www.benzinga.com/news/earnings/25/02/43461109/how-to-earn-500-a-month-from-alphabet-stock-ahead-of-q4-earnings",
            "pub_date": "2025-02-05 02:37:39",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "67a25ebe9d57a90001d506dd",
            "title": "Palantir Focused ETFs Spark Investor Interest: Here&#39;s Why",
            "description": "ETFs are becoming popular for investors looking for exposure to high-growth stocks without single-stock risk. Palantir&#39;s strong Q4 earnings make it a top holding in 4 ETFs, including ARKK, SHLD, and FPX.",
            "image": "https://www.benzinga.com/files/images/story/2025/02/04/The-Palantir-Trade_0.jpeg",
            "link": "https://www.benzinga.com/25/02/43473966/why-smart-money-is-turning-to-these-palantir-focused-etfs",
            "pub_date": "2025-02-05 02:38:57",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "67a25cc99d57a90001d505d7",
            "title": "Behind the Scenes of Apple&#39;s Latest Options Trends",
            "description": " ",
            "image": "https://www.benzinga.com/files/images/story/2023/movers_image_0.jpeg",
            "link": "https://www.benzinga.com/insights/options/25/02/43473693/behind-the-scenes-of-apples-latest-options-trends",
            "pub_date": "2025-02-05 02:30:36",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "67a25d119d57a90001d50618",
            "title": "Cumberland Pharmaceuticals&#39; Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease",
            "description": "Cumberland Pharmaceuticals&#39; Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.",
            "image": "https://www.benzinga.com/files/images/story/2025/02/04/CPIX.png",
            "link": "https://www.benzinga.com/general/biotech/25/02/43473776/cumberland-pharmaceuticals-duchenne-candidate-shows-improved-heart-function-in-patients-with-associated-heart-disease",
            "pub_date": "2025-02-05 02:31:48",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "67a25daa9d57a90001d5064f",
            "title": "Cardinal Health Analysts Raise Their Forecasts Following Upbeat Earnings",
            "description": " ",
            "image": "https://www.benzinga.com/files/images/story/2025/02/04/cardinalhealth-Company.jpeg",
            "link": "https://www.benzinga.com/25/02/43473832/cardinal-health-analysts-raise-their-forecasts-following-upbeat-earnings-2",
            "pub_date": "2025-02-05 02:34:21",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}